1. CCLHD Research

Michael F Back

View Statistics Email Alert RSS Feed

Profile

Loading... 2 0 20 0 false
Credit Name
Michael F Back
Full Name
Back, Michael F
ORCID
Loading... 3 0 20 0 false

Publications

Results 1-20 of 81 (Search time: 0.007 seconds).

Issue DateTitleAuthor(s)
1Jan-2022Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapyJayamanne, Dasantha ; Wong, Matthew ; Back, Michael F 
2Oct-2021A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU studyBack, Michael F 
3Sep-2021Emerging Evidence of the Gut Microbiome in Chemotherapy: A Clinical ReviewBack, Michael F 
4Jul-2021Improving efficiency in the radiation management of multiple brain metastases using a knowledge-based planning solution for single-isocentre volumetric modulated arc therapy (VMAT) techniqueBack, Michael F 
59-Jun-2021Redo craniotomy or bevacizumab for symptomatic steroid-refractory true or pseudoprogression following IMRT for glioblastomaCook, Theresa A ; Jayamanne, Dasantha ; Wong, Matthew ; Cove, Nicola ; Back, Michael F 
6May-2021The Gut Microbiome and Gastrointestinal Toxicities in Pelvic Radiation Therapy: A Clinical ReviewBack, Michael F ; Eade, Thomas ; Kneebone, Andrew 
7Feb-2021Radiation oncology during COVID-19: Strategies to avoid compromised careBack, Michael F 
8Dec-2020An Innovative Tai Chi and Qigong Telehealth Service in Supportive Cancer Care During the COVID-19 Pandemic and BeyondBack, Michael F 
9Dec-2020Effects of acupuncture on cancer-related fatigue: a meta-analysisBack, Michael F 
10Dec-2020Hypofractionated adjuvant surgical cavity radiotherapy following resection of limited brain metastasisBack, Michael F 
11Nov-2020Introducing Computed Tomography Simulation-Free and Electronic Patient-Reported Outcomes-Monitored Palliative Radiation Therapy into Routine Care: Clinical Outcomes and Implementation ExperienceBack, Michael F 
12Mar-2020The role of large volume re-irradiation with Bevacizumab in chemorefractory high grade gliomaWong, Matthew ; Jayamanne, Dasantha ; Back, Michael F 
13Jun-2019Reflecting on survivorship outcomes to aid initial decision making in patients treated for IDH-mutated anaplastic gliomaBack, Michael F ; Jayamanne, Dasantha ; Wong, Matthew 
14May-2019Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastomaCuncannon, Moire ; Wong, Matthew ; Jayamanne, Dasantha ; Cove, Nicola ; Back, Michael F 
15Apr-2019Influence of molecular classification in anaplastic glioma for determining outcome and future approach to managementBack, Michael F ; Jayamanne, Dasantha ; Wong, Matthew 
16Apr-2019Pattern of failure in anaplastic glioma patients with an IDH1/2 mutationBack, Michael F ; Jayamanne, Dasantha ; Wong, Matthew 
17Apr-2019Focal radiation therapy for limited brain metastases is associated with high rates of local control and low subsequent whole brain radiation therapyJayamanne, Dasantha ; Stevens, Mark ; Back, Michael F 
18Dec-2018FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes - A pilot studyBack, Michael F ; Jayamanne, Dasantha 
19Nov-2018Tumour volume reduction following PET guided intensity modulated radiation therapy and temozolomide in IDH mutated anaplastic gliomaBack, Michael F ; Jayamanne, Dasantha 
20Oct-2018Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer CentreBack, Michael F ; Jayamanne, Dasantha ; Wong, Matthew